Respiratory Drugs Market is forecast to rise from a value of $28.1 Respiratory Drugs Market 2022 | Page 2

The COPD and asthma treatment landscapes employ similar symptomatic treatments, including
bronchodilators and inhaled corticosteroids.
However, over the past decade the treatment of respiratory disorders has developed significantly,
as has the importance for novel therapies and targeted therapies. The approval of the products
Orkambi and Kalydeco, in 2014 and 2012 respectively, gave patients disease-modifying treatment
options for CF. Another important entry was the first biologic drug - omalizumab - approved in
2014 for the treatment of severe asthma. The trend of developing targeted therapies continued
with the approval of the maintenance treatment Nucala (mepolizumab) in November 2015.
Although the more traditional non-specific symptomatic therapies continue to have a strong
presence in the respiratory disorder pipeline, the pipeline also contains promising targeted biologic
therapies, which reflects their growing prominence in this therapy area. Overall, 908 products are
currently in active in development for respiratory disorders.
Read Sample report of this Category:
http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare
Scope
The respiratory disorders market is characterized by entrenched, commercially successful
therapies.
- Which classes of drug dominate the market?
- What additional benefits have newly approved therapies brought to the market?
- What are the future prospects for the leading brands?
The pipeline contains a range of molecule types and molecular targets, with a growing presence of
targeted therapies.
- Which molecular targets appear most frequently in the pipeline?
- What are the commercial prospects for the most promising late-stage pipeline products?
Respiratory disorders clinical trials have an overall attrition rate of 89.1%.
- What are the failure rates at individual phases of clinical development?
- How do the key respiratory disorders compare in terms of clinical trial failure rate?
The respiratory disorders market is forecast to rise from a value of $28.1 billion in 2015 to $46.6
billion in 2022, at a CAGR of 7.5%.
- How much of a role will pipeline product approvals play in market growth?
Follow Us: